ALB and ovarian adenocarcinoma: In a follow-up study in the same tumour model (i.e., C3Hf/KamLaw mice bearing ∼7 mm syngeneic OCa-1 ovarian adenocarcinomas), similar results were reported for Abraxane, that is, for albumin-based paclitaxel, which also beneficially combined both with single dose and with fractionated radiotherapy, and which did not increase normal tissue radiotoxicity (Wiedenmann et al, 2007).